ABCL

AbCellera Biologics Inc. (ABCL) ESG Analysis Analysis (2026)

Invetso Score: 5.8/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Environmental

No material environmental controversies or disclosures were provided in the fresh data.

Capital intensity remains meaningful, with capex to revenue at 37.4% and capex to operating cash flow at 0.16x, suggesting ongoing resource use to support operations.

Social

No material social news was provided this month.

R&D intensity remains very high at 299.0% of revenue, indicating continued investment in innovation and talent.

Governance

The balance sheet remains strong, with a current ratio of 12.8x and low debt-to-equity of 0.15x, supporting financial resilience.

Governance risk is tempered by low leverage, but valuation remains stretched at 52.5x sales while profitability is still negative.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on AbCellera Biologics Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →